IP Library Granted Patent US 6,933,303
Granted Patent B2
US 6,933,303 · App. 10/274,546 · Granted Aug 23, 2005

Heteroaryl-fused nitrogen heterocycles as therapeutic agents

Assignee: TransTech Pharma, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,933,303
App. No.
10/274,546
Granted
Aug 23, 2005
Kind
B2
Abstract

This invention provides compounds which are useful as inhibitors of protein tyrosine phosphatases (PTPases). As inhibitors of PTPases, the compounds of the invention are useful for the management, treatment, control and adjunct treatment of diseases mediated by PTPase activity. Such diseases include type I diabetes, type II diabetes, immune dysfunction, AIDS, autoimmunity, glucose intolerance, obesity, cancer, psoriasis, allergic diseases, infectious diseases, inflammatory diseases, diseases involving the modulated synthesis of growth hormone or the modulated synthesis of growth factors or cytokines which affect the production of growth hormone, or Alzheimer's disease.

Claims (85)

1. A compound of Formula (I):

wherein

R 1 is

1,1′-biphenyl-4-yl; cyclohexyl; 4-bromo, chloro, or fluorophenyl; 2,4-dichlorophenyl; 4-benzyloxyphenyl; 4-(4-carboxy)benzyloxphenyl; cyclopentyl; (E)-2-phenylvinylphenyl; indol-3-yl; 4-hydroxyphenyl; 4-hydroxybenxyl; 1-benxylindol-3-yl; or 1-butylindol-3-yl;

R 2 is

(a) hydrogen;

(b) alkyl; alkenyl; alkynyl;

(c) heterocyclyl; cycloalkyl;

(d) -alkylene-aryl; -alkenylene-aryl; -alkynylene-aryl; -alkyloxy-aryl,

(e) -alkylene-heteroaryl; -alkenylene-heteroaryl; -alkynylene-heteroaryl; -alkoxy-heteroaryl;

(f) -alkylene-heterocyclyl; -alkenylene-heterocyclyl; -alkynylene-heterocyclyl or

(g) —C(O)—OR 7 ; -alkylene-C(O)—OR 7 ; -alkenylene-C(O)—OR 7 ; -alkynylene-C(O)—OR 7 , —C(O)—NR 7 R 8 ; -alkylene-C(O)—NR 7 R 8 ; -alkenylene-C(O)—NR 7 R 8 ; -alkynylene-C(O)—NR 7 R 8 , -alkylene-O-aryl; -alkylene-O-alkylene-aryl; -alkylene-O-cycloalkyl; —(SO 2 )—R 7 ; -alkylene-S(O 2 )—R 7 ; -alkenylene-S(O 2 )—R 7 ; -alkynylene-S(O 2 )—R 7 ; -alkylene-S(O)—R 7 ; -alkenylene-S(O)—R 7 ; -alkynylene-S(O)—R 7 ; -alkylene-S(O 2 )—R 7 ; -alkenylene-S(O 2 )—R 7 ; -alkynylene-S(O 2 )—R 7 ; —S(O 2 )NR 7 R 8 ; -alkylene-S(O 2 )—NR 7 R 8 ; -alkenylene-S(O 2 )—NR 7 R 8 ; or -alkynylene-S(O 2 )—NR 7 R 8 ; wherein

R 7 and R 8 independently comprise hydrogen, aryl, alkyl, or -alkylene-aryl; or R 7 and R 8 may be taken together to form a ring having the formula —(CH 2 ) m —T—(CH 2 ) n — bonded to the nitrogen atom to which R 7 and R 8 are attached, wherein

m and n are, independently, 1, 2, 3, or 4; T comprises —CH 2 —, —C(O)—, —O—, —N(H)—, —S—, —S(O)—, —S(O 2 )—, —CON(H)—, —NHC(O)—, —NHC(O)N(H)—, —NH(SO 2 )—, —S(O 2 )N(H)—, —(O)CO—, —NHS(O 2 )NH—, —OC(O)—, —N(R 9 )—, —N(C(O)R 9 )—, —N(C(O)NHR 9 )—, —N(S(O 2 )NHR 9 )—, —N(SO 2 R 9 )—, or —N(C(O)OR 9 )—; or

R 7 and R 8 may be taken together, with the nitrogen atom to which they are attached, to form a heterocyclyl or heteroaryl ring;

R 3 is

(a) hydrogen;

(b) alkyl; alkenyl; alkynyl;

(c) -alkylene-aryl; -alkenylene-aryl; -alkynylene-aryl;

(d) -alkylene-heteroaryl; -alkenylene-heteroaryl or -alkynylene-heteroaryl;

A 2 is —NR 10 R 11 , or —NR 10 A 4 ;

wherein

R 10 and R 11 are independently selected from the group consisting of:

(a) hydrogen;

(b) alkyl; alkenyl; alkynyl;

(c) heterocyclyl; cycloalkyl;

(d) aryl; heteroaryl; -arylene-aryl; -arylene-heteroaryl; -heteroarylene-aryl; -heteroarylene-heteroaryl; -alkylene-aryl; -alkenylene-aryl; -alkynylene-aryl; -alkyloxy-aryl; -alkylene-heteroaryl, -alkenylene-heteroaryl, -alkynylene-heteroaryl, -alkoxy-heteroaryl,

(e) -alkylene-heterocyclyl; -alkenylene-heterocyclyl; -alkynylene-heterocyclyl;

(f) -arylene-L 2 -alkylene-aryl, -arylene-L 2 -alkylene-heteroaryl, -arylene-alkylene-L 2 -heteroaryl, -arylene-alkylene-L 2 -aryl, -alkylene-arylene-L 2 -alkylene-aryl, -alkylene-L 2 -aryl, -alkylene-L 2 -arylene-aryl, -alkylene-arylene-L 2 -alkylene-C(O)O-alkyl, -alkylene-arylene-L 2 -alkylene-C(O)OH, -alkylene-arylene-L 2 -alkylene-C(O)NH-alkyl, -alkylene-arylene-L 2 -alkylene-heteroaryl, -alkylene-arylene-alkylene-L 2 -aryl, -alkylene-arylene-alkylene-L 2 -heteroaryl; wherein L 2 comprises O, —C(O)—, S, —S(O)—, —S(O 2 )—, a direct bond;

(g) —C(O)—OR 12 , -alkylene-C(O)—OR 12 , -alkenylene-C(O)—OR 12 , -alkynylene-C(O)—OR 12 , —C(O)—NR 12 R 13 , -alkylene-C(O)—NR 12 R 13 , -alkenylene-C(O)—NR 12 R 13 , alkynylene-C(O)—NR 12 R 13 , -alkylene-O-aryl, -alkylene-O-alkylene-aryl, -alkylene-O-cycloalkyl, —S(O 2 )—R 12 , -alkylene-S(O 2 )—R 12 , -alkenylene-S(O 2 )—R 12 , -alkynylene-S(O 2 )—R 12 , -alkylene-S(O)—R 12 , -alkenylene-S(O)—R 12 , -alkynylene-S(O)—R 12 , -alkylene-S(O)—R 12 , -alkenylene-S(O)—R 12 , -alkynylene-S(O)—R 12 , —S(O 2 )—NR 12 R 13 , -alkylene-S(O 2 )—NR 12 R 13 , -alkenylene-S(O 2 )—NR 12 R 13 , and -alkynylene-S(O 2 )—NR 12 R 13 ;

wherein R 10 and R 11 may be taken together with the nitrogen atom to which they are attached, to form a heterocycyl or heteroaryl ring;

wherein

R 12 and R 13 are independently selected from the group consisting of hydrogen, aryl, alkyl, and alkylene-aryl; or

R 12 and R 13 may be taken together to form a ring having the formula —(CH 2 ) s —V—(CH 2 ) t — bonded to the nitrogen atom to which R 12 and R 13 are attached, wherein

s and t are, independently, 1, 2, 3, or 4; V is —CH 2 —, —C(O)—, —O—, —N(H)—, —S—, —S(O)—, —S(O 2 )—, —CON(H)—, —NHC(O)—, —NHC(O)N(H)—, —NHS(O 2 ), —S(O 2 )N(H)—, —(O)CO—, —NHS(O 2 )NH—, —OC(O)—, —N(R 14 )—, —N(C(O)R 14 )—, —N(C(O)NHR 14 )—, —N(SO 2 NHR 14 )—, —N(S(O 2 )R 14 )—, or —N(C(O)OR 14 )—; or

R 12 and R 13 may be taken together, with the nitrogen atom to which they are attached, to form a heterocyclyl or heteroaryl ring;

A 4 is

wherein

L 3 is alkyline, alkenyline, heteroaryline, aryline, cycloalkyline, or heterocyclyline group;

L 4 is a direct bond, —C(O)—N(R 15 )—, —C(O)—O—, —C(O)—, or —N(R 15 )—CO—N(R 16 )—, -alkylene-C(O)—N(R 15 )—, -alkylene-C(O)—O—, -alkylene-C(O)—, or -alkylene-N(R 15 )—CO—N(R 16 )—;

L 5 is H, alkyl, alkenyl, alkynyl, heterocyclyl, heteroaryl, or -alkylene-aryl;

L 6 is hydrogen, alkyl, alkenyl, alkynyl, -alkylene-aryl, -alkylene-heteroaryl, -alkylene-O-alkylene-aryl, -alkylene-arylene-O-alkylene-aryl, -alkylene-S-alkylene-aryl, -alkylene-O-alkyl, -alkylene-S-alkyl, -alkylene-NH 2 , -alkylene-OH, -alkylene-SH, alkylene-cycloalkyl, alkylene-heterocyclyl, cycloalkyl, heterocyclyl, alkylene-arylene-aryl, arylene-aryl, -alkylene-C(O)—OR 17 , -alkylene-C(O)—NR 17 R 18 , -alkylene-NR 17 R 18 , -alkylene-N(R 17 )—C(O)—R 18 , or -alkylene-N(R 17 )—S(O 2 )—R 18 ;

wherein

R 17 and R 18 are independently selected from the group consisting of hydrogen, aryl, alkyl, and alkylene-aryl; or

R 17 and R 18 may be taken together to form a ring having the formula —(CH 2 ) o —P—(CH 2 ) w — bonded to the nitrogen atom to which R 17 and R 18 are attached, wherein

o and w are, independently, 1, 2, 3, or 4; P is —CH 2 —, —C(O)—, —O—, —N(H)—, —S—, —S(O)—, —S(O 2 )—, —CON(H)—, —NHC(O)—, —NHC(O)N(H)—, —NHS(O 2 ), —S(O 2 )N(H)—, —(O)CO—, —NHS(O 2 )NH—, —OC(O)—, —N(R 19 )—, —N(C(O)R 19 )—, —N(C(O)NHR 19 )—, —N(SO 2 NHR 19 )—, —N(S(O 2 )R 19 )—, or —N(C(O)OR 19 )—; or

R 17 and R 18 may be taken together with the nitrogen atom to which they are attached to form a heterocyclyl or heteroaryl ring;

R 9 , R 14 , R 15 , R 16 , and R 19 are independently selected from the group consisting of hydrogen, aryl, alkyl, and alkylene-aryl;

A 1 is O; S; or NR 20 , where R 20 is:

(a) hydrogen;

(b) alkyl;

(c) alkenyl; alkynyl; helerocyclyl; cycloalkyl; -alkylene-aryl; -alkenylene-aryl; -alkynylene-aryl; -alkyloxy-aryl; -alkylene-heteroaryl; -alkenylene-heteroaryl; -alkynylene-heteroaryl; -alkoxy-heteroaryl; -alkylene-heterocyclyl; -alkenylene-heterocyclyl; -alkynylene-heterocyclyl;

(d) -alkylene-C(O)—OR 21 ; -alkenylene-C(O)—OR 21 ; -alkynylene-C(O)—OR 21 ; —C(O)—NR 21 R 22 ; -alkylene-C(O)—NR 21 R 22 ; -alkenylene- C(O)—NR 21 R 22 ; —alkynylene-C(O)—NR 21 R 22 ; -alkylene-O-aryl; -alkylene-O-alkylene-aryl; -alkylene-O-cycloalkyl; —S(O 2 )—R 21 ; -alkylene-S(O 2 )—R 21 ; -alkenylene-S(O 2 )—R 21 ; -alkynylene-S(O 2 )—R 21 ; -alkylene-S(O)—R 21 ; -alkenylene-S(O)—R 21 ; -alkynylene-S(O)—R 21 ; alkylene-S(O)—R 21 ; -alkenylene-S(O)—R 21 ; -alkynylene-S(O)—R 21 ; —S(O 2 )—NR 21 R 22 ; -alkylene-S(O 2 )—NR 21 R 22 ; -alkenylene-S(O 2 )—NR 21 R 22 ; or -alkynylene-S(O 2 )—NR 21 R 22 ; wherein

R 21 and R 22 are independently selected from the group consisting of hydrogen, aryl, alkyl, and alkylene-aryl; or

R 21 and R 22 may be taken together to form a ring having the formula —(CH 2 ) x —Z—(CH 2 ) y — bonded to the nitrogen atom to which R 14 and R 15 are attached; wherein

x and y are, independently, 1, 2, 3, or 4; Z is —CH 2 —, —C(O)—, —O—, —N(H)—, —S—, —S(O)—, —S(O 2 )—, —C(O)N(H)—, —NHC(O)—, —NHC(O)N(H)—, —NHS(O 2 )—, —S(O 2 )N(H)—, —(O)CO—, —NHS(O 2 )H—, —OC(O)—, —N(R 23 )—, —N(C(O)R 23 )—, —N(C(O)NHR 23 )—, —N(S(O 2 )NHR 23 )—, —N(S(O 2 )R 23 )—, or —N(C(O)OR 23 )—; or

R 21 and R 22 may be taken together, with the nitrogen atom to which they are attached, to form a heterocyclyl or heteroaryl ring;

A 3 is —CH 2 —;

Ar 1 is, taken together with the double bond in Formula (I), aryl;

R 4 , R 5 , and R 6 are independently selected from the group consisting of

(a) hydrogen;

(b) aryl, heteroaryl;

(c) heterocyclyl; cycloalkyl;

(d) -alkylene-Y-aryl; -alkenylene-Y-aryl; -alkynlene-Y-aryl; alkylene-Y-heteroaryl, -alkenylene-Y-heteroaryl; -alkynlene-Y-heteroaryl; -alkylene-Y-cycloalkyl; -alkenylene-Y-cycloalkyl; -alkynlene-Y-cycloalkyl; -alkylene-Y-heterocyclyl; -alkenylene-Y-heterocyclyl; alkynlene-Y-heterocyclyl; —Y—H; —Y-alkyl; —Y-aryl; —Y-alkylene-aryl; —Y-alkylene-NR 24 R 25 ; —Y—O—Si-(alkyl) 3 ; and —Y—O—Si-(alkylene-aryl) 3 ;

wherein

Y is —CH 2 —, —O—, —N(H)—, —S—, —S(O)—, S(O 2 )—, —C(O)N(H)—, —NHC(O)—, —NHC(O)N(H)—, —NHS(O 2 ), —S(O 2 )N(H)—, —C(O)—O—, —C(NH)—O—, —NHS(O 2 )H—, or —O—C(O)—;

R 24 and R 25 are independently selected from the group consisting of hydrogen, aryl, alkyl, and alkylene-alyl; or

R 24 and R 25 may be taken together to form a ring having the formula —(CH 2 ) q —Q—(CH 2 ) r — bonded to the nitrogen atom to which R 24 and R 25 are attached, wherein

q and r are, independently, 1, 2, 3, or 4; Q is —CH 2 —, —O—, —N(H)—, —S—, —S(O)—, —S(O 2 ), —CON(H)—, —NHC(O)—, —NHC(O)N(H)—, —NHS(O 2 )—, —S(O 2 )N(H)—, —(O)CO—, —NHS(O 2 )H—, —OC(O)—, —N(R 26 )—, —N(C(O)R 26 )—, —N(C(O)NHR 26 )—, —N(S(O 2 )NHR 26 )—, —N(S(O 2 )R 26 )— or —N(C(O)OR 26 )—; or

R 24 and R 25 may be taken together, with the nitrogen atom to which they are attached, to form a heterocyclyl or heteroalyl ring;

R 23 and R 26 are independently selected from the group consisting of hydrogen, aryl, alkyl, and alkylene-aryl;

or a pharmaceutically acceptable salt, or solvate thereof.

2. The compound of Formula (I) of claim 1 , wherein R 4 , R 5 , and R 6 are independently selected from the group consisting of hydrogen, alkyl, carboxy, and alkylcarbamoyl.

3. The compound of Formula (I) of claim 1 , wherein A 1 is NR 20 , wherein R 20 is hydrogen, or alkyl.

4. The compound of Formula (I) of claim 1 , wherein R 2 is a hydrogen or an alkyloxycarbonyl group.

5. The compound of Formula (I) of claim 1 , wherein A 2 is —NR 10 R 11 , or —NR 10 A 4 , wherein R 10 and R 11 are independently selected from the group consisting of hydrogen, alkyl, heterocyclyl, cycloalkyl, benzyl, 3-Fluorophenyl, 2-(3-Fluorophenyl)-1-ethyl, 2,4,6-Trimethoxybenzyl, 4-tert-Butylbenzyl, 4-Chlorobenzyl, 4-Carboxybenzyl, 2(4-(methoxycarbonylmethoxy)-phenyl-1-ethyl, (R)-1-Methoxycarbonyl-1-(4-hydroxyphenyl)methyl, or 1-Hydroxymethyl-1-(1,1′-Biphenyl-4-yl)methyl and A 4 comprises 1,1′-Biphenyl-4-yl; 1-Benzylcarbamoyl-1-(1,1′-Biphenyl-4-yl)methyl; (5-methyl-2-furan)methyl; 4-(methoxycarbonylmethyl)-1-phenyl; 4-(Carboxymethyl)-1-phenyl; 4-Methoxycarbonyl-1-cyclohexyl; 1-Methoxycarbonyl-1-(1,1′-Biphenyl-4-yl)methyl; 1-(1,1′-Biphenyl-4-yl)1-carboxymethyl; (R)-1-Methoxycarbonyl-1-(4-hydroxybenzyl)methyl; 1-Methylcarbamoyl-1-(1,1′-Biphenyl-4-yl)methyl; 2-[4-(benzyloxy)phenyl]-1-carboxy-1-ethyl; 1-Dimethylaminocarbamoyl-1-(1,1′-Biphenyl-4-yl)methyl; 2-(1,1′-Biphenyl-4-yl)1-methoxycarbonyl-1-ethyl; 1-Benzyloxycarbonyl-1-(1,1′-Biphenyl-4-yl)methyl; 1-Propoxycarbonyl-1-(1,1′-Biphenyl-4-yl)methyl; 1-Butoxycarbonyl-1-(1,1′-Biphenyl-4-yl)methyl; 1-(2-Methoxy-1-ethoxycarbonyl)-1-(1,1′-Biphenyl-4-yl)methyl; 1-Methoxymethyl-1-(1,1′-Biphenyl-4-yl)methyl; Benzothiazol-2-yl; 1-(2-Hydroxy-1-propylcarbamoyl-1-(1,1′-Biphenyl-4-yl)methyl; and 1-(2-Oxo-1-propylcarbamoyl-1-(1,1′-Biphenyl-4-yl)methyl.

6. The compound of Formula (I) of claim 1 , wherein R 4 , R 5 , and R 6 are independently selected from the group consisting of hydrogen, alkyl, carboxy, and alkylcarbamoyl; A 1 is NR 20 , wherein R 20 is hydrogen, or alkyl; R 2 is a hydrogen or an alkyloxycarbonyl group; and A 2 is NR 10 R 11 , or —NR 10 A 4 , wherein R 10 and R 11 are independently selected from the group consisting of hydrogen; alkyl; heterocyclyl, cycloalkyl, benzyl, 3-Fluorophenyl, 2-(3-Fluorophenyl)-1-ethyl, 2,4,6-Trimethoxybenzyl, 4-tert-Butylbenzyl, 4-Chlorobenzyl, 4-Carboxybenzyl, 2(4-(methoxycarbonylmethoxy)-phenyl-1-ethyl, (R)-1-Methoxycarbonyl-1-(4-hydroxyphenyl)methyl, or 1-Hydroxymethyl-1-(1,1′-Biphenyl-4-yl)methyl and A 4 comprises 1,1′-Biphenyl-4-yl; 1-Benzylcarbamoyl-1-(1,1′-Biphenyl-4-yl)methyl; (5-methyl-2-furan)methyl; 4-(methoxycarbonylmethyl)-1-phenyl; 4-(Carboxymethyl)-1-phenyl; 4-Methoxycarbonyl-1-cyclohexyl; 1-Methoxycarbonyl-1-(1,1′-Biphenyl-4-yl)methyl; 1-(1,1′-Biphenyl-4-yl)1-carboxymethyl; (R)-1-Methoxycarbonyl-1-(4-hydroxybenzyl)methyl; 1-Methylcarbamoyl-1-(1,1′-Biphenyl-4-yl)methyl; 2-[4-(benzyloxy)phenyl]-1-carboxy-1-ethyl; 1-Dimethylaminocarbamoyl-1-(1,1′-Biphenyl-4-yl)methyl; 2-(1,1′-Biphenyl-4-yl)1-methoxycarbonyl-1-ethyl; 1-Benzyloxycarbonyl-1-(1,1′-Biphenyl-4-yl)methyl; 1-Propoxycarbonyl-1-(1,1′-Biphenyl-4-yl)methyl; 1-Butoxycarbonyl-1-(1,1′-Biphenyl-4-yl)methyl; 1-(2-Methoxy-1-ethoxycarbonyl)-1-(1,1′-Biphenyl-4-yl)methyl; 1-Methoxymethyl-1-(1,1′-Biphenyl-4-yl)methyl; Benzothiazol-2-yl; 1-(2-Hydroxy-1-propylcarbamoyl-1-(1,1′-Biphenyl-4-yl)methyl; and 1-(2-Oxo-1-propylcarbamoyl-1-(1,1′-Biphenyl-4-yl)methyl.

7. The compound of Formula (I) of claim 1 , wherein the compound is:

Benzyl 1-(1,1′-biphenyl-4-yl)-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 3-Fluorophenyl 1-(1,1′-biphenyl-4-yl)-2-tert-butoxycarbonyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 2-(3- Fluorophenyl)-1-ethyl 1-(1,1′-Biphenyl-4-yl)-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 1,1′-Biphenyl-4-yl (1S,3S)-1-(1,1′-Biphenyl-4-yl)-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 1-Benzylcarbamoyl-1-(1,1′-Biphenyl-4-yl)methyl (1S,3S)-1-(1,1′-Biphenyl-4-yl)-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 2,4,6-Trimethoxybenzyl (1S,3R)-1-Cyclohexyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 4-tert-Butylbenzyl (1S,3R)-1-(1,1′-Biphenyl-4-yl)-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 2,4,6-Trimethoxybenzyl (1S,3R)-1-(4-bromophenyl)-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, (5-methyl-2-furan)methyl (1S,3R)-1-(1,1′-Biphenyl-4-yl)-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 4-Chlorobenzyl (1S,3R)-1-(2,4-dichlorophenyl)-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 2,4,6-Trimethoxybenzyl (1S,3R)-1-(4-benzyloxyphenyl)-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 4-Carboxybenzyl (1S,3R)-1-(1,1′-Biphenyl-4-yl)-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 2,4,6-Trimethoxybenzyl (1S,3R)-1-(4-(4-carboxy)benzyloxyphenyl)-2-tert-butoxycarbonyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 4-(methoxycarbonylmethyl)-1-phenyl (1S,3R)-1-(1,1′-Biphenyl-4-yl)-2-tert-butoxycarbonyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 2,4,6-Trimethoxybenzyl 1-(1,1′-Biphenyl-4-yl)-6-methylcarboximidatoyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 2,4,6-Trimethoxybenzyl 1-(1,1′-Biphenyl-4-yl)-6-methoxycarbonyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 4-(Carboxymethyl)-1-phenyl (1S,3R)-1-(1,1′-Biphenyl-4-yl)-2-tert-butoxycarbonyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 4-(Carboxymethyl)-1-phenyl (1S,3R)-1-(1,1′-Biphenyl-4-yl)-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 4-Methoxycarbonyl-1-cyclohexyl (1S,3R)-1-(1,1′-Biphenyl-4-yl)-2-tert-butoxycarbonyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 2(4-(methoxycarbonylmethoxy)-phenyl-1-ethyl (1S,3R)-1-(1,1′-Biphenyl-4-yl)-2-tert-butoxycarbonyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, (5-Methyl-2-furan)methyl (1R, 3S)-1-(1,1′-Biphenyl-4-yl)-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 2,4,6-Trimethoxybenzyl 1-Cyclopentyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 2,4,6-Trimethoxybenzyl 1-(1,1′-Biphenyl-4-yl)-6-carboxy-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 1-Methoxycarbonyl-1-(1,1′-Biphenyl-4-yl)methyl (3R)-1-(1,1′-Biphenyl-4-yl)-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 2,4,6-Trimethoxybenzyl (1R,3R)-1-{4-[(E)-2-phenylvinyl]phenyl}-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 2,4,6-Trimethoxybenzyl 1-(1,1′-Biphenyl-4-yl)-6-butylcarbamoyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 2,4,6-Trimethoxybenzyl (1S,3R)-1-(Indol-3-yl)-2-tert-butoxycarbonyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 2,4,6-Trimethoxybenzyl (1R,3R)-1-(Indol-3-yl)-2-tert-butoxycarbonyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 2,4,6-Trimethoxybenzyl (1S,3R)-1-(Indol-3-yl)-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 2,4,6-Trimethoxybenzyl (1R,3R)-1-(Indol-3-yl)-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, (R)-1-Methoxycarbonyl-1-(4-hydroxyphenyl)methyl (1S)-1-(1,1′-Biphenyl-4-yl)-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, (R)-1-Methoxycarbonyl-1-(4-hydroxyphenyl)methyl (1R)-1-(1,1′-Biphenyl-4-yl)-2-tert-butoxycarbonyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 1-(1,1′-Biphenyl-4-yl)1-carboxymethyl (1S,3R)-1 Cyclohexyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 1-(1,1′-Biphenyl-4-yl)1-carboxymethyl (1R,3R)-1 Cyclohexyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, (R)-1-Methoxycarbonyl-1-(4-hydroxybenzyl)methyl (1S)-1-(1,1′-Biphenyl-4-yl)-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 1-Methoxycarbonyl-1-(1,1′-Biphenyl-4-yl)methyl (1S,3R)-1-Cyclohexyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 1-Methoxycarbonyl-1-(1,1′-Biphenyl-4-yl)methyl (1R,3R)-1-Cyclohexyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 1-Carboxy-1-(1,1′-Biphenyl-4-yl)methyl (1S,3R)-1-(4-Bromophenyl)-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 1-Carboxy-1-(1,1′-Biphenyl-4-yl)methyl (1R,3R)-1-(4-Bromophenyl)-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 1-Methoxycarbonyl-1-(1,1′-Biphenyl-4-yl)methyl (1S,3R)-1-(4-Bromophenyl)-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 1-Methoxycarbonyl-1-(1,1′-Biphenyl-4-yl)methyl (1R,3R)-1-(4-Bromophenyl)-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 1-Methylcarbamoyl-1-(1,1′-Biphenyl-4-yl)methyl (1S,3R)-1-Cyclohexyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 1-Methylcarbamoyl-1-(1,1′-Biphenyl-4-yl)methyl (1R,3R)-1-Cyclohexyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 2-[4-(benzyloxy)phenyl]-1-carboxy-1-ethyl (1S,3R)-1-Cyclohexyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 2-[4-(benzyloxy)phenyl]-1-carboxy-1-ethyl (1R,3R)-1-Cyclohexyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 2-[4-(benzyloxy)phenyl]-1-methoxycarbonyl-1-ethyl (1S,3R)-1-Cyclohexyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 2-[4-(benzyloxy)phenyl]-1-methoxycarbonyl-1-ethyl (1R,3R)-1-Cyclohexyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 1-Dimethylaminocarbamoyl-1-(1,1′-Biphenyl-4-yl)methyl (1S,3R)-1-Cyclohexyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 1-Dimethylaminocarbamoyl-1-(1,1′-Biphenyl-4-yl)methyl (1R,3R)-1-Cyclohexyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 1-Hydroxymethyl-1-(1,1′-Biphenyl-4-yl)methyl (1S,3R)-1-Cyclohexyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 2-(1,1′-Biphenyl-4-yl)1-methoxycarbonyl-1-ethyl (1S,3R)-1-Cyclohexyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 2-(1,1′-Biphenyl-4-yl)1-methoxycarbonyl-1-ethyl (1R,3R)-1-Cyclohexyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 2-(1,1′-Biphenyl-4-yl) 1-carboxy-1-ethyl (1S,3R)-1 Cyclohexyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 2-(1,1′-Biphenyl-4-yl)1-carboxy-1-ethyl (1R,3R)-1-Cyclohexyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 1-Benzyloxycarbonyl-1-(1,1′-Biphenyl-4-yl)methyl (1R,3R)-1-Cyclohexyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 1-Methoxycarbonyl-1-(1,1′-Biphenyl-4-yl)methyl (1R,3R)-1-Cyclohexyl-2-tert-butoxycarbonyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, (3R)-1-(1-benzylindol-3-yl)-2-tert-butoxycarbonyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxylic Acid, (3R)-1-(1-butylindol-3-yl)-2-tert-butoxycarbonyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxylic Acid, 1-Methoxycarbonyl-1-(1,1′-Biphenyl-4-yl)methyl (3R)-1-(1-butylindol-3-yl)-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 1-Methoxycarbonyl-1-(1,1′-Biphenyl-4-yl)methyl (3R)-1-(1-butylindol-3-yl)-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 1-Dimethylcarbamoyl-1-(1,1′-biphenyl-4-yl)methyl (1S,3R)-1-(1,1′-Biphenyl-4-yl)-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, (1S,3R)-1-(Indol-3-yl)-2-tert-butoxycarbonyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxylic Acid, 1-(2,4,6-trimethoxybenzylcarbamoyl)-1-(1,1′-Biphenyl-4-yl)methyl (1S,3R)-1-Cyclohexyl-2-tert-butoxycarbonyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 1-Benzyloxycarbonyl-1-(1,1′-Biphenyl-4-yl)methyl (1S,3R)-1-(1,1′-Biphenyl-4-yl)-2-tert-butoxycarbonyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 1-Propoxycarbonyl-1-(1,1′-Biphenyl-4-yl)methyl (1S,3R)-1-Cyclohexyl-2-tert-butoxycarbonyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 1-Butoxycarbonyl-1-(1,1′-Biphenyl-4-yl)methyl (1S,3R)-1-Cyclohexyl-2-tert-butoxycarbonyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 1-(2-Methoxy-1-ethoxycarbonyl)-1-(1,1′-Biphenyl-4-yl)methyl (1S,3R)-1-Cyclohexyl-2-tert-butoxycarbonyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 1-Methoxymethyl-1-(1,1′-Biphenyl-4-yl)methyl (3R)-1-Cyclohexyl-2-tert-butoxycarbonyl-9-methyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 1-Methoxymethyl-1-(1,1′-Biphenyl-4-yl)methyl (3R)-1-Cyclohexyl-9-methyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, (1S,3R)-1-(1-methylindol-3-yl)-2-tert-butoxycarbonyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid, 1-(2,4,6-trimethoxybenzylcarbamoyl)-1-(1,1′-Biphenyl-4-yl)methyl (1S,3R)-1-Cyclohexyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 1-(Benzyloxycarbonyl)-1-(1,1′-Biphenyl-4-yl)methyl (1S,3R)-1-(1,1′-Biphenyl-4-yl)-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 1-Propoxycarbonyl-1-(1,1′-Biphenyl-4-yl)methyl (1S,3R)-1-Cyclohexyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 1-Butoxycarbonyl-1-(1,1′-Biphenyl-4-yl)methyl (1S,3R)-1-Cyclohexyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 1-(2-Methoxy-1-ethoxycarbonyl)-1-(1,1′-Biphenyl-4-yl)methyl (1S,3R)-1-Cyclohexyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, Benzothiazol-2-yl (1S,3R)-1-Cyclohexyl-2-tert-butoxycarbonyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, Benzothiazol-2-yl (1S,3R)-1-Cyclohexyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 1,1′-Biphenyl-4-oylmethyl (1S,3R)-1-Cyclohexyl-2-tert-butoxycarbonyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxylate, 1,1′-Biphenyl-4-oylmethyl (1R,3R)-1-Cyclohexyl-2-tert-butoxycarbonyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxylate, 2,4,6-Trimethoxybenzyl (1S,3R)-1-(1-methylindol-3-yl)-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 2,4,6-Trimethoxybenzyl (1S,3R)-1-(1-methylindol-3-yl)-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide, 1,1′-Biphenyl-4-oylmethyl (1S)-1-Cyclohexyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxylate, 1-(2-Hydroxy-1-propylcarbamoyl-1-(1,1′-Biphenyl-4-yl)methyl (1S,3R)-1-Cyclohexyl-2-tert-butoxycarbonyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide or 1-(2-Oxo-1-propylcarbamoyl-1-(1,1′-Biphenyl-4-yl)methyl (1S,3R)-1-Cyclohexyl-2-tert-butoxycarbonyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide.

8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound of Formula (I) as claimed in claim 1 .

9. The pharmaceutical composition of claim 8 , in the form of an oral dosage or parenteral dosage unit.

10. The pharmaceutical composition of claim 8 , wherein said compound is administered as a dose in a range from about 0.01 to 500 mg/kg of body weight per day.

11. The pharmaceutical composition of claim 8 , wherein said compound is administered as a dose in a range from about 0.1 to 200 mg/kg of body weight per day.

12. The pharmaceutical composition of claim 8 , wherein said compound is administered as a dose in a range from about 0.1 to 100 mg/kg of body weight per day.

13. The pharmaceutical composition of claim 8 , further comprising one or more therapeutic agents selected from the group consisting of alkylating agents, antimetabolites, plant alkaloids, antibiotics, hormones, biologic response modifiers, analgesics, NSAIDS, DMARDS, glucocorticoids, sulfonylureas, biguanides, insulin, choliflesterase inhibitors, antipsychotics, antidepressants, and anticonvulsants.

Assignments (10)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA PREVIOUSLY RECORDED AT REEL: 036254 FRAME: 0780. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 24, 2015
From: M&F TTP HOLDINGS LLC, AS COLLATERAL AGENT
To: VTVX HOLDINGS I LLC
Reel/Frame 036675/0407 →
RELEASE OF SECURITY INTEREST Recorded Aug 3, 2015
From: M&F TTP HOLDINGS LLC, AS COLLATERAL AGENT
To: VTVX HOLDINGS II LLC
Reel/Frame 036254/0780 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2015
From: VTVX HOLDINGS I LLC
To: VTV THERAPEUTICS LLC
Reel/Frame 036242/0354 →
CHANGE OF NAME Recorded Jul 30, 2015
From: VTV THERAPEUTICS LLC
To: VTVX HOLDINGS I LLC
Reel/Frame 036236/0165 →
CHANGE OF NAME Recorded Jun 25, 2015
From: TRANSTECH PHARMA, LLC
To: VTV THERAPEUTICS LLC
Reel/Frame 036026/0219 →
SECURITY INTEREST Recorded Feb 26, 2015
From: TRANSTECH PHARMA, LLC
To: M&F TTP HOLDINGS LLC, AS COLLATERAL AGENT
Reel/Frame 035103/0356 →
NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS FOR REEL/FRAME 030982/0803 Recorded Apr 7, 2014
From: M&F TTP HOLDINGS LLC
To: TRANSTECH PHARMA, LLC
Reel/Frame 032621/0860 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2013
From: TRANSTECH PHARMA, INC.
To: TRANSTECH PHARMA, LLC
Reel/Frame 031654/0878 →
SECURITY AGREEMENT Recorded Aug 9, 2013
From: TRANSTECH PHARMA, INC.
To: M&F TTP HOLDINGS LLC C/O MACANDREWS & FORBES HOLDINGS INC.
Reel/Frame 030982/0803 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 30, 2002
From: MJALLI, ADNAN M.M.; ANDREWS, ROBERT C.; XIE, RONGYUAN; YARRAGUNTA, RAVINDRA R.; REN, TAN
To: TRANSTECH PHARMA, INC.
Reel/Frame 013624/0226 →
Continuity (3)
Provisional Application 6034612500 · Oct 19, 2001
Provisional Application 6034617600 · Oct 19, 2001
Related Publication 20040014778A1 · Jan 22, 2004